Navigation Links
Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
Date:7/22/2009

INDIANAPOLIS, July 22 /PRNewswire/ -- Roche Diagnostics announced today the introduction of the Roche Cardiac 200, a comprehensive testing solution for rapid cardiac diagnostic needs in point-of-care testing environments.

The latest addition to an expanding portfolio of Roche Diagnostics cardiac solutions, the Roche Cardiac 200 is a lateral flow immunoassay testing system designed to provide quantitative cardiac marker test results on whole blood samples with a turnaround time of only 10 to 19 minutes, to help meet best practice guidelines for emergency department settings.

Patients who present to the emergency department (ED) with symptoms of a cardiovascular event are typically tested for a series of "cardiac markers," or chemicals that the body releases as an indication of recent heart damage or potential cardiovascular problems. Often the ED physicians treating these patients cannot afford to wait for traditional testing methods, which can take longer than 60 minutes.

The Roche Cardiac 200 can process up to 36 tests per hour and offers a full cardiac marker menu that includes NT-proBNP, Troponin I (TnI), CKMB and Myoglobin. The instrument uses a unique internal corrected fluorescence measurement technology to deliver accuracy and reliability that are consistent with the performance expectations of laboratory systems as defined by the National Academy of Clinical Biochemistry (NACB).(1) Studies have shown that Roche Cardiac 200 diagnostic results for NT-proBNP and Troponin I are essentially equivalent to core lab results. (2, 3, 4)

The Roche Cardiac 200 offers an easy-to-read touch screen and flexible modular configurations to enable labs to address specific workflow needs. It also uses a proprietary internal standard that eliminates the need for routine recalibration.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2008, sales by the Pharmaceuticals Division totalled 36.0 billion Swiss francs, and the Diagnostics Division posted sales of 9.7 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interest in Chugai, and invested nearly 9 billion Swiss francs in R&D in 2008. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law. RAMP is a trademark of Response Biomedical Corporation.

    For further information, please contact:
    Doyia Turner
    Corporate Communications
    Roche Diagnostics Corporation
    Indianapolis, IN
    (317) 521-7252
    (317) 694-0335 (cell)
    doyia.turner@roche.com

(1) Christenson R. The National Academy of Clinical Biochemistry. Laboratory Medicine Practice Guidelines: Biomarkers of acute coronary syndrome and heart failure. 2007.

(2) Lee-Lewandrowski E, Januzzi J, Greene S, Tannous B, Wu A, Smith A, Wong A, Murkami MA, Kaczmarek J, Apple F, Miller W, Hartman K, Jaffe A. Multi-Center Validation of the Response Biomedical Corporation RAMP(R) NT-proBNP Assay with Comparison to the Roche Diagnostics Gmbh Elecsys(R) proBNP Assay 2007; 386:20-24. The Roche Cardiac 200 was formerly known as the RAMP system from Response Biomedical Corporation.

(3) Offner M, Winckel E, Jung A, Lamy T, Arthur G, Zucker M. Clinical Comparison for Exclusion of Acute Heart Failure Using the RAMP(R) and Dade Dimension RxL(R) NT-proBNP Assays. Annual Meeting and Clinical Lab Expo, 2007. The Roche Cardiac 200 was formerly known as the RAMP system from Response Biomedical Corporation.

(4) Wu AHB, Smith A, Christenson RH, Murakami MM, Apple FS. Evaluation of a Point-of-Care Assay for Cardiac Markers for Patients Suspected of Acute Myocardial Infarction. Clin Chim Acta 2004;346:211-219 [b].


'/>"/>
SOURCE Roche Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
2. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
3. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
4. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
5. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
6. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
7. Rochester Medical Corporation Set to Join Russell 3000 Index
8. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
9. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
10. moksha8 Expands Alliance With Roche to Commercialize $200 Million of Products in Brazil and Mexico
11. Roches Pierson Honored as 2009 HBA Rising Star
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Bunion ... knowns as a bunionette) treatment was more than humbled by customer demand over the ... of their SKU's mid sale. Now that Bunion Bootie has completely replenished its inventory ...
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National Eye ... and international water advocate, was honored by Ashram, Inc. as the world’s foremost water ... knelt on the banks of the Nile to fill their red clay pots with ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our professional athletes coincides ... HEAD ™”. , “We are proud to introduce Meghan Klingenberg, defender and ... have Brian Quick, wide receiver for Los Angeles who was a second round selection ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... Morrow-Fox . With over 20 years of experience in leading technology and human ... several years of university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica ...
(Date:5/26/2016)... NY (PRWEB) , ... May 26, 2016 , ... May ... lips been so central to popular cosmetic improvement efforts. Record numbers of clients now ... appear more prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... CHESTERFIELD, Va. , May 25, 2016 /PRNewswire/ ... next-generation sequencing test for wounds and infections. This ... ALL parasites, and select viruses. The test requires ... area. David G. Bostwick ... molecular testing to facilitate wound healing: "We are ...
Breaking Medicine Technology: